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Left Ventricular Dysfunction in Patients
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Robert W. Carlson, MD,† Ronald M. Witteles, MD*
Stanford, California; and Denver, Colorado
Objectives The purpose of this study was to examine treatment practices for cancer therapy-associated decreased left ven-
tricular ejection fraction (LVEF) detected on echocardiography and whether management was consistent with
American College of Cardiology/American Heart Association guidelines.
Background Patients treated with anthracyclines or trastuzumab are at risk of cardiotoxicity. Decreased LVEF represents a
Class I indication for drug intervention according to American College of Cardiology/American Heart Association
guidelines.
Methods Patients receiving anthracycline or trastuzumab at Stanford University from October 2005 to October 2007 and
who had undergone echocardiography before and after receiving an anthracycline or trastuzumab were identi-
fied. Chart review examined chemotherapy regimens, cardiac risk factors, imaging results, concomitant medica-
tions, and cardiology consultations.
Results Eighty-eight patients received therapy with an anthracycline or trastuzumab and had a pre-treatment and
follow-up echocardiogram. Ninety-two percent were treated with anthracyclines, 17% with trastuzumab after an
anthracycline, and 8% with trastuzumab without previous treatment with anthracycline. Mean baseline LVEF was
60%, with 14% having a baseline 55%. Forty percent had decreased LVEF (55%) after anthracycline and/or
trastuzumab treatment. Of these patients, 40% received angiotensin-converting enzyme inhibitor or angiotensin
receptor blocker therapy, 51% beta-blocker therapy, and 54% cardiology consultation. Of patients with asymp-
tomatic decreased LVEF, 31% received angiotensin-converting enzyme inhibitor or angiotensin receptor blocker
therapy, 35% beta-blocker therapy, and 42% cardiology consultation. Of those with symptomatic decreased
LVEF, 67% received angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy, 100% beta-
blocker therapy, and 89% cardiology consultation.
Conclusions Many cancer survivors are not receiving treatment consistent with heart failure guidelines. There is substantial
opportunity for collaboration between oncologists and cardiologists to improve the care of oncology patients
receiving cardiotoxic therapy. (J Am Coll Cardiol 2010;56:1644–50) © 2010 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.07.023n
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ihe understanding and treatment of heart failure and
ecreased left ventricular ejection fraction (LVEF) have
ndergone a radical change during the past 2 decades. It is
rom the *Division of Cardiovascular Medicine, Stanford University School of
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chool of Medicine, Stanford, California; and the ‡Division of Cardiovascular
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atsuda has served as a consultant to Medicure Pharma. All other authors have
eported that they have no relationships to disclose. This work was presented as an
bstract at the 2009 American College of Cardiology 58th Annual Scientific Session,
rlando, Florida, March 29 to 31, 2009, at the 2009 American College of Cardiology
onsumer Interest Press Conference, March 28, 2009, and at the 2009 Annual
eeting of the American Society of Clinical Oncology, Orlando, Florida, May 29 to
une 2, 2009.c
Manuscript received October 19, 2009; revised manuscript received July 15, 2010;
ccepted July 18, 2010.ow understood that institution of medical therapy can
ften prevent or reverse progressive left ventricular (LV)
ysfunction and is ideally instituted before heart failure
ymptoms develop (1). Heart failure is generally thought to
e a progressive clinical syndrome with symptoms of con-
estion occurring late in the natural history of the disease.
s such, current treatment guidelines emphasize prevention
nd early intervention for at-risk individuals and individuals
ith asymptomatic decreased LVEF (1).
Asymptomatic decreased LVEF can lead to a markedly
ncreased risk of the development of congestive heart failure
nd death (2). Asymptomatic decreased LVEF is a Class I
ndication for therapy with beta-blockers and angiotensin-
onverting enzyme inhibitors (ACEIs) or angiotensin receptor
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y/American Heart Association guidelines (1,3).
Anthracyclines and trastuzumab are used to treat cancer
nd have known cardiotoxicity. Anthracyclines such as
oxorubicin directly damage the myocardium through pro-
uction of oxygen free radicals, leading to LV dysfunction
nd, in some cases, an irreversible cardiomyopathy (4). This
oxicity is cumulative and dose dependent with an incidence
f clinically detected heart failure in 2.2% of patients
eceiving doxorubicin at a median dose of 390 mg/m2 (5).
mportantly, these early studies focused only on patients in
hom symptomatic heart failure developed.
Studies incorporating prospective LVEF monitoring dem-
nstrate that asymptomatic cardiotoxicity is common, even at
ower cumulative doses. The most commonly accepted defini-
ion of decreased LVEF in the oncology community is an
bsolute 10-point decrease in LVEF from baseline or an
VEF 50% (6). Prospective studies have observed
oxorubicin-related decreased LVEF in 16%, 38%, and 65% of
atients receiving doxorubicin cumulative doses of 300 mg/m2,
50 mg/m2, and 550 mg/m2, respectively (7).
Trastuzumab (Herceptin, Genentech, South San Fran-
isco, California) is a humanized monoclonal antibody
gainst the extracellular domain of HER2 and is part of the
tandard treatment for breast cancer with HER2 overex-
ression and/or amplification. In the pivotal phase III
linical trial, a 27% incidence of cardiac dysfunction was
bserved in metastatic breast cancer patients treated with
oncurrent doxorubicin and trastuzumab, and 13% in pa-
ients treated with concurrent trastuzumab and paclitaxel,
lmost all of whom had received previous anthracycline
herapy (8). Subsequent studies in patients with early-stage
reast cancer demonstrated symptomatic heart failure in as
any as 4% and asymptomatic decreased LVEF in as
any as 14% of patients treated sequentially with
nthracycline- and trastuzumab-containing regimens
9 –14). Due to the known cardiotoxicity of trastuzumab,
he package insert recommends baseline LVEF assess-
ent and reassessment every 3 months during and upon
ompletion of this therapy (15).
In clinical oncology practice, asymptomatic decreases in
VEF are the most commonly encountered form of cardio-
oxicity (7,16). We designed this study to examine how
linicians have been treating cancer patients with decreased
VEF after exposure to anthracyclines and/or trastuzumab
nd specifically to examine whether the care provided after
iagnosis of decreased LVEF is consistent with the Amer-
can College of Cardiology/American Heart Association
uidelines.
ethods
fter institutional review board approval, we identified all
atients who received anthracycline and/or trastuzumab cancer
herapy at Stanford University from October 1, 2005, to
ctober 31, 2007, using an institutional pharmacy database. A total of 974 patients received an
nthracycline and/or trastuzumab
uring this time period. We identi-
ed all unique patients who had at
east 1 echocardiogram (echo) per-
ormed before and after the start of
hemotherapy using an institutional
chocardiography database. All
chos were 2-dimensional trans-
horacic echos, and all were inter-
reted by cardiologists at Stanford
niversity.
During the time period of this
tudy, some patients receiving an
nthracycline and/or trastuzumab
ad cardiac monitoring with mul-
iple gated acquisition (MUGA) scan. To compare patients
ho underwent MUGA imaging with patients who under-
ent echocardiographic imaging, we used a random number
enerator to choose 400 charts from the original chemotherapy
atabase. Among this group, 88 patients were identified who
ad MUGA imaging performed before anthracycline and/or
rastuzumab exposure and represented our comparison cohort.
Detailed chart review was then conducted examining
emographic data including age, sex, cancer disease character-
stics, cancer therapy type and dose, presence of pre-existing
ardiac disease and cardiac risk factors, cardiac imaging indi-
ation and results, concomitant medications, and cardiology
onsultations. We also examined individual charts to deter-
ine whether a contraindication to beta-blocker or ACEI/
RB therapy existed. Patients in both inpatient and outpatient
ettings were evaluated in this study.
Patients were defined as having decreased LVEF if they
ad an LVEF 55%, according to our institutional stan-
ard. We defined symptomatic decreased LVEF as an
VEF 55% with the presence of dyspnea, orthopnea,
ulmonary edema, lower extremity edema, and/or ascites
hat clinicians attributed to congestive heart failure. We
ecorded the background rate at Stanford Hospital and
linics for the treatment of LV systolic dysfunction with
CEI/ARB therapy from Hospital Compare data (17).
tatistical analysis. Descriptive statistics were used to
alculate the number of patients experiencing decreased
VEF, both with and without symptoms. For patients with
n LVEF 55%, we calculated the proportion of patients
ho received: 1) ACEI/ARB therapy; 2) beta-blocker
herapy; and 3) cardiology consultation. Odds ratios (ORs)
nd their 95% confidence intervals (CIs) were used to
valuate the relationship of cardiac risk factors to the
evelopment of decreased LVEF.
esults
atient characteristics. A total of 88 patients met inclu-
ion criteria. Their baseline characteristics before the start of
Abbreviations
and Acronyms
ACEI  angiotensin-
converting enzyme inhibitor
ARB  angiotensin
receptor blocker
CI  confidence interval
echo  echocardiogram
LV  left ventricular
LVEF  left ventricular
ejection fraction
MUGA  multiple gated
acquisition
OR  odds ratioreatment with cardiotoxic chemotherapy are listed in Table 1.
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Left Ventricular Dysfunction After Chemotherapy November 9, 2010:1644–50resence of pre-existing coronary artery disease and cardiac
isk factors of hypertension, diabetes, and hypercholesterol-
mia are listed in Table 1. Other pre-existing cardiac
iseases were noted: 1 patient had pulmonary hypertension,
patient had a ventricular septal defect, 1 patient had a
istory of supraventricular tachycardia, and 1 patient had a
istory of orthotopic heart transplantation for ischemic
ardiomyopathy. Seventeen patients were screened for car-
iac ischemic disease before chemotherapy with stress
quilibrium-gated nuclear angiocardiography, stress echo-
ardiography, and/or cardiac catheterization, resulting in
he diagnosis of coronary artery disease in 3 patients.
Patients in the study had a baseline LVEF of 60% (8%).
ifteen patients (17%) were taking ACEI/ARBs and
6 patients (18%) were taking beta-blockers before
hemotherapy.
The majority of patients had breast cancer (32%) or acute
yelogenous leukemia (32%). A breakdown of the malig-
ancies treated is included in Table 2. Table 3 lists chemo-
herapy regimens and cumulative doses. Most patients
92%) received anthracyclines. Seven patients (8%) received
rastuzumab and had no exposure to an anthracycline.
ifteen patients (17%) received trastuzumab after exposure
o an anthracycline.
atients experiencing decreased LVEF. A total of 88
atients had echos before and after the start of cancer
herapy. The mean follow-up from the start of cancer
herapy to the last follow-up echo was 11.9  11.7 months.
ommon indications for ordering echos after chemotherapy
ancer Diagnosis (n  88)Table 2 Cancer Diagnosis (n  88)
Breast cancer, n (%) 28 (32)
Acute myelogenous leukemia, n (%) 28 (32)
Chronic myelogenous leukemia, n (%) 2 (2)
Acute lymphoblastic leukemia, n (%) 9 (10)
Non-Hodgkin’s lymphoma, n (%) 11 (13)
Hodgkin’s lymphoma, n (%) 2 (2)
aseline Characteristics of Patients (n  88)Table 1 Baseline Characteristics of Patients (n  88)
Mean age, yrs (range) 51.6 (23–78)
Sex, n (%)
Male 41 (47)
Female 47 (53)
Baseline LVEF, %  SD 60 8
Patients with baseline LVEF below normal, n (%) 12 (14)
Cardiac risk factors, n (%)
Coronary artery disease 6 (7)
Diabetes mellitus 15 (17)
Hypercholesterolemia 23 (26)
Hypertension 28 (32)
Taking ACEI/ARBs, n (%) 15 (17)
Taking beta-blockers, n (%) 16 (18)
CEI  angiotensin-converting enzyme inhibitor; ARB  angiotensin receptor blocker; LVEF  left
entricular ejection fraction.ncluded post-chemotherapy surveillance, chest pain, fever,
nd suspected pericardial disease.
A total of 35 patients had decreased LVEF after the start
f chemotherapy. Twelve patients had a baseline LVEF
elow normal before chemotherapy and had a diagnosis of a
ow LVEF as outpatients. In 23 patients, a low LVEF
eveloped after cancer therapy, and 22 of these patients
96%) had a diagnosis of a low LVEF as outpatients.
Of the 35 total patients who had a decreased LVEF after
he start of chemotherapy, 14 (40%) received ACEI/ARB
herapy, 18 (51%) received beta-blocker therapy, and 19
54%) received cardiology consultation (Fig. 1). The back-
round rate at Stanford Hospital and Clinics for the
reatment of LV systolic dysfunction with ACEI/ARB
herapy is 98% (17).
Nine patients in the study had symptomatic decreased
VEF after the start of chemotherapy. Six patients (67%) in
his cohort received ACEI/ARB therapy, 9 (100%) received
ancer Therapy and Cumulative Dose (n  88)Table 3 Cancer Therapy and Cumulative Dose (n  88)
Cancer Therapy n (%) Cumulative Dose (Mean  SD)
All anthracyclines 81 (92) N/A
Doxorubicin 49 (56) 238 167 mg/m2
Daunorubicin 17 (19) 216 112 mg/m2
Idarubicin 15 (17) 40 9 mg/m2
Trastuzumab with no exposure
to anthracycline
7 (8) 210 161 mg/kg
Trastuzumab after exposure to
anthracycline
15 (17) 91 73 mg/kg (trastuzumab)
/A  not applicable.
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Figure 1
Percentage of Patients Who Received ACEIs/ARBs,
Beta-Blockers, and/or Cardiology Consultation After
the Start of Chemotherapy
Open bars on the bar graph represent the percentage of patients with left ven-
tricular ejection fraction (LVEF) 55% who received angiotensin-converting
enzyme inhibitors or angiotensin receptor blockers (ACEIs/ARBs), beta-block-
ers, and/or cardiology consultation. Blue bars represent the percentage of
patients with a symptomatic LVEF 55%, and red bars represent the percent-
age of patients with an asymptomatic LVEF 55% who received ACEI/ARBs,
beta-blockers, and/or cardiology consultation.Other, n (%) 8 (9)
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November 9, 2010:1644–50 Left Ventricular Dysfunction After Chemotherapyeta-blocker therapy, and 8 (89%) received cardiology con-
ultation (Fig. 1). Of the 8 patients with symptomatic
ecreased LVEF who received cardiology consultation, 5
63%) received ACEI/ARB therapy and 100% received
eta-blocker therapy. The 1 patient with symptomatic
ecreased LVEF who did not receive cardiology consulta-
ion received ACEI/ARB and beta-blocker therapy.
Twenty-six patients in the study had asymptomatic de-
reased LVEF after the start of chemotherapy. Eight
atients (31%) with asymptomatic decreased LVEF re-
eived ACEI/ARB therapy, 9 (35%) received beta-blocker
herapy, and 11 (42%) received cardiology consultation
Fig. 1). Of the 11 patients with asymptomatic decreased
VEF who received cardiology consultation, 5 (45%) re-
eived ACEI/ARB therapy and 4 (36%) received beta-
locker therapy. Of the 15 patients with asymptomatic
ecreased LVEF who did not receive cardiology consulta-
ion, 3 (20%) received ACEI/ARB therapy and 4 (27%)
eceived beta-blocker therapy.
Within the group of patients with asymptomatic or
ymptomatic decreased LVEF, there were no allergies to
CEI/ARB therapy or beta-blockers. For patients with
ecreased LVEF, physician assessment after diagnosis of
ecreased LVEF on echocardiography did not document
ny contraindications to receiving ACEI/ARB therapy or
eta-blocker therapy. All 35 patients who had decreased
VEF had a creatinine clearance30 ml/min at the start of
heir anthracycline or trastuzumab treatment, as determined
y the Cockcroft-Gault formula (18).
Of the 21 patients who had decreased LVEF and did not
eceive ACEI/ARBs, 12 had anemia with a mean hemo-
lobin level of 10.6  1.1 g/dl (range 9.2 to 11.9 g/dl)
uring physician assessment after a diagnosis of decreased
VEF. None of the 21 patients in this cohort had fatigue or
ypotension (systolic blood pressure 100 mm Hg and/or
iastolic blood pressure 60 mm Hg) during physician
ssessment after a diagnosis of decreased LVEF.
Of the 16 patients who had decreased LVEF and did not
eceive beta-blockers, 10 had anemia with a mean hemo-
lobin level of 10.5  1.0 g/dl (range 9.3 to 11.9 g/dl)
uring physician assessment after a diagnosis of decreased
VEF. None of the 16 patients in this cohort had fatigue or
ypotension (systolic blood pressure 100 mm Hg and/or
iastolic blood pressure 60 mm Hg) during physician
ssessment after a diagnosis of decreased LVEF.
otential risk factors for cardiotoxicity. Twenty-one pa-
ients had a baseline LVEF that was normal and a decreased
VEF developed after the start of anthracycline or trastu-
umab therapy. Only hypercholesterolemia (OR: 3.76, 95%
I: 1.29 to 11.0; p  0.014) was associated with the
evelopment of decreased LVEF after the start of chemo-
herapy, whereas age older than 65 years (OR: 1.06, 95%
I: 0.340 to 3.39; p  0.920), male sex (OR: 2.57, 95% CI:
.954 to 6.89; p  0.062), coronary artery disease (OR:
.59, 95% CI: 0.296 to 8.64; p 0.624), hypertension (OR:
.926, 95% CI: 0.330 to 2.62; p  0.888), and diabetes
*ellitus (OR: 1.36, 95% CI: 0.419 to 4.46; p 0.623) were
ot associated with the development of decreased LVEF,
lthough our small sample size makes the power to detect
linically meaningful associations quite low.
Thirteen patients (15%) had left chest wall radiation
herapy and 7 patients (8%) had mediastinal radiation
herapy. Mediastinal and left chest wall radiation was not
ssociated with the development of decreased LVEF (OR:
.22, 95% CI: 0.464 to 10.677, p  0.346 and OR: 0.444,
5% CI: 0.100 to 2.03; p  0.316, respectively), although
he numbers were small.
All 4 patients with other cardiac risk factors (pulmonary
ypertension, supraventricular tachycardia, ventricular sep-
al defect, and post-transplantation status) had a baseline
VEF 55%, and progressed to a decreased LVEF after
he start of anthracycline or trastuzumab therapy.
omparison between MUGA and echo groups. Tables 4
nd 5 compare 88 patients who received MUGA imaging
ith the 88 study patients who received an echo before
ancer therapy. There was no statistically significant differ-
nce in deaths between MUGA and echo groups during the
tudy period, as shown in Table 5 (p  0.71). There was
lso no difference in deaths in patients with an LVEF55%
etween MUGA and echo groups (p  0.21).
Patients who had MUGA imaging before cancer therapy
nd who had a low LVEF after cancer therapy actually had
ower rates of receiving beta-blockers and cardiology con-
ultation compared with the echo group, as shown in Table 5
6% received beta-blockers vs. 51% in the echo group
aseline Characteristics of Patients Whond rw nt MUGA Imaging Compared Withchocardiographic Imaging Before Cancer Therapy
Table 4
B seline Charact ristics of Patients Who
Underwent MUGA Imaging Compared With
Echocardiographic Imaging Before Cancer Therapy
MUGA
(n  88)
Echo
(n  88)
p
Value*
Mean age, yrs (range) 56.4 (29–89) 51.6 (23–78) 0.01
Sex, n (%)
Male 18 (20) 41 (47) 0.001
Female 70 (80) 47 (53) 0.001
Baseline LVEF, %  SD 65.8 8.6 60 8 0.001
Patients with baseline LVEF below
normal, n (%)
7 (8) 12 (14) 0.23
Cardiac risk factors, n (%)
Coronary artery disease 1 (1) 6 (7) 0.054
Diabetes mellitus 10 (11) 15 (17) 0.28
Hypercholesterolemia 13 (15) 23 (26) 0.06
Hypertension 20 (23) 28 (32) 0.18
Taking ACEI/ARBs, n (%) 13 (15) 15 (17) 0.68
Taking beta-blockers, n (%) 7 (8) 16 (18) 0.04
Cancer diagnosis, n (%)
Breast cancer 55 (63) 28 (32) 0.001
Acute myelogenous leukemia 1 (1) 28 (32) 0.001
Chronic myelogenous leukemia 0 (0) 2 (2) 0.16
Non-Hodgkin’s lymphoma 18 (20) 11 (13) 0.16
Hodgkin’s lymphoma 2 (2) 2 (2) 1.0
Other 12 (14) 8 (9) 0.34p value calculated using chi-square analysis.
echo  echocardiogram; MUGA multiple gated acquisition; other abbreviations as in Table 1.
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Left Ventricular Dysfunction After Chemotherapy November 9, 2010:1644–50p  0.05]; 19% received cardiology consultation vs. 54% in
he echo group [p  0.05]). There was no difference in
hose who received ACEI/ARB therapy between MUGA
nd echo groups for patients with a low LVEF (25%
eceived ACEI/ARB vs. 40% in the echo group [p 0.30]).
atient deaths. Of the 35 patients with a low LVEF, 10
29%) died during the study period. Four patients had a
aseline LVEF 55% diagnosed as outpatients before
ancer therapy. Of these 4 patients with a decreased baseline
VEF, 1 received ACEI/ARB therapy, 3 received beta-
locker therapy, and 1 received cardiology consultation.
ecreased LVEF developed in 6 patients after cancer
herapy, and diagnosed with outpatient echocardiograms.
f these 6 patients, 3 (50%) received ACEI/ARBs, 4 (67%)
eceived beta-blockers, and 3 (50%) received cardiology
onsultation.
Of the original 88 patients in the study, 18 died during
he study period. Eleven patients died of septic shock, 3 of
alignancy, 2 of noncardiac respiratory failure, and 1 of
ntracranial hemorrhage. One patient died of ventricular
achycardia in the setting of severe hypokalemia due to
ntifungal therapy. There were no deaths from congestive
eart failure. Of the patients who died, 9 had acute
yelogenous leukemia, 5 had acute lymphoblastic leukemia,
had chronic myelogenous leukemia, 1 had non-Hodgkin’s
ymphoma, 1 had Hodgkin’s lymphoma, and 1 had breast
ancer.
iscussion
his is the first study to evaluate cardiovascular treatment
nd referral practices for cancer patients with treatment-
elated decreased LVEF. Our study demonstrates that many
ancer patients with asymptomatic decreased LVEF are not
eceiving cardiovascular care consistent with guideline rec-
mmendations. Specifically, many patients with asymptom-
tic decreased LVEF are not receiving American College of
ardiology/American Heart Association Class I-indicated
eta-blocker or ACEI/ARB therapy. Many patients with
eaths and Cardiovascular Treatments of Patientsho Underwent MUGA Imaging Compared Withchocar iograph c Imaging B fore Canc r Therapy
Table 5
Deaths and C rdiovascular Treatments of Patients
Who Underwent MUGA Imaging Compared With
Echocardiographic Imaging Before Cancer Therapy
MUGA
(n  88)
Echo
(n  88) p Value*
Deaths, n (%) 20 (23) 18 (20) 0.71
LVEF 55%, n (%) 16 (18) 35 (40) 0.002
Deaths within group LVEF 55%, n (%) 2 (13) 10 (29) 0.21
Cardiovascular treatments, n (%)
Patients with LVEF 55% who
received ACEI/ARB
4 (25) 14 (40) 0.30
Patients with LVEF 55% who
received beta-blocker
1 (6) 18 (51) 0.002
Patients with LVEF 55% who
received cardiology consultation
3 (19) 19 (54) 0.02
p value calculated using chi-square analysis.
Abbreviations as in Tables 1 and 4.symptomatic decreased LVEF are also not receiving car- viovascular specialty consultation. In contrast, the majority
f patients who developed symptomatic decreased LVEF
elated to cardiotoxic cancer therapy received treatment with
CEI/ARB therapy, beta-blocker therapy, and cardiology
onsultation.
The reasons for the lack of treatment and referral of
atients experiencing asymptomatic decreased LVEF were
ot evaluated in our study. Possible explanations include a
ack of knowledge of these treatment guidelines by the
linicians who care for these patients or beliefs among
hysicians that these declines in cardiac function are tran-
ient and reversible. Patient-related factors may also be
elevant as patients may focus on their cancer treatment
rimarily and neglect or de-emphasize other aspects of their
eneral medical care.
Our data demonstrate that many in our cohort had cancer
iagnoses with poor prognoses, and we observed a high rate
f mortality during our study period; this may be yet another
actor that influenced the decision not to institute cardiac-
pecific treatment in cases of asymptomatic decreased
VEF, particularly in patients with acute leukemia. None-
heless, the majority of patients with decreased LVEF were
iagnosed as outpatients. As noted earlier, further review of
he cases did not yield any other contraindications such as
ypotension, fatigue, and severe anemia to explain the lack
f treatment. In addition, patients in our study in whom
ecreased LVEF developed and who died during the study
eriod had higher rates of receiving ACEI/ARB and
eta-blocker therapy compared with the entire cohort with
n LVEF 55%, although the numbers were small. Given
he complex nature of heart failure cases among patients
ith cancer, it may be advisable to involve heart failure
pecialists early after the diagnosis of a decreased LVEF
ecause heart failure survival has been demonstrated to
mprove with specialty care (19).
Transient decreases in the LVEF can occur after exposure
o anthracyclines or trastuzumab. The long-term signifi-
ance of transient decreases in LVEF during cancer therapy
s not well-known, although data suggest that the response
o injury of various causes is similar, with negative remod-
ling leading to progressive LV dysfunction over time (1).
nitial recovery of LV function does not imply that the
njury was “reversible” and without future consequence.
arly decreases in the LVEF after chemotherapy may be
ssociated with significant cardiotoxicity at a later time (20).
n this study, we do not know whether subsequent imaging
eyond the study’s follow-up period showed an improve-
ent in the LVEF.
Currently, given a paucity of long-term follow-up data,
here is no clear way to predict which patients will develop
ransient versus worsening declines in their LVEF after
hemotherapy, and clinicians may find it challenging to
ecide whether to start ACEI/ARBs and beta-blocker
herapy. In similar situations with myocardial injury, such as
ith an episode of myocardial infarction, myocarditis, and
arious nonischemic heart failure causes, transient decreases
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ention. These patients may be at increased risk of subse-
uent LV dysfunction and clinical heart failure, and it is on
his basis that many of these patients, particularly after
yocardial infarction, receive ACEI/ARB and beta-blocker
herapy regardless of their LV function, as is clearly recom-
ended in current heart failure treatment guidelines (1).
During the study period, there were no deaths from heart
ailure and no hospitalizations due to heart failure. The
atients who died in this study died of a variety of causes,
ot including heart failure, and it is unclear whether
reatment with ACEI/ARBs and beta-blockers is specifi-
ally valuable in this patient population.
As shown by the SOLVD (Studies of Left Ventricular
ysfunction) investigators (3), treatment of asymptomatic
ecreased LVEF of various causes with ACE inhibition has
een shown to decrease the incidence of symptomatic heart
ailure and improve outcomes. However, it is not clear
hether treatment of asymptomatic decreased LVEF in
ancer patients specifically decreases the risk of symptomatic
eart failure. There are no prospective studies evaluating
hether the treatment of asymptomatic decreased LVEF
educes hospitalizations or improves longevity or quality of
ife in this population. Observational studies show a higher
ncidence of LVEF recovery in cancer patients with a
ecreased LVEF treated with ACEI/ARBs (21,22). These
ata suggest that cancer patients who experience a decreased
VEF may have a response similar to that in patients in the
eneral population with decreased LVEF who receive Class
-indicated therapy.
tudy limitations. Our study was limited by the retrospec-
ive nature of the available data. Although it is possible that
e may have missed cardiology consultations and medical
herapies received outside our institution, we extensively
eviewed the chart for any updated medications and referrals
efore, during, and after cancer therapy.
Many patients who received cardiotoxic cancer therapy at
ur institution during the study period were excluded from
he study based on the lack of echos before and after the
tart of chemotherapy. Although there are professional
ociety recommendations for pre- and post-chemotherapy
chocardiographic screening, such as suggested by the
merican Society of Echocardiography (23), these recom-
endations are not uniform, particularly among oncology
ocieties. Many patients who received cardiotoxic cancer
herapy at our institution may not have had an assessment of
V function after cancer therapy because there are no clear
uidelines for post-cancer therapy screening. Many patients
xcluded from the study may have had cardiac monitoring
erformed using MUGA scans. This study focused on
linicians’ responses to decreased LVEF found during
ardiac screening by echocardiography rather than on the
ates of screening studies performed. In addition, the choice
f using MUGA versus echocardiography for assessment of
V function is predominantly practitioner-dependent at ournstitution. Regardless of which imaging modality deter-ined a decrease in LVEF, guideline-based therapy would
ecommend treatment with beta-blockers and ACEI/ARBs
nless an appropriate contraindication was present.
Our study is also limited by the relatively small sample
ize, which limits the statistical power to detect clinically
eaningful associations with risk factors, specific agents,
nd diseases. Previous studies have observed advanced age,
ypertension, diabetes mellitus, coronary artery disease, and
adiation as risk factors for the development of decreased
VEF from chemotherapy (7,24–26). Our study found that
nly hypercholesterolemia was associated with the develop-
ent of decreased LVEF in patients who had normal
VEFs before chemotherapy. Due to the lack of statistical
ower for these subjects, these results should be interpreted
ith caution. There is potential for further investigation
egarding the relationship between hypercholesterolemia
nd cardiotoxicity, as studies in mice have shown that pre-
reatment with statins may help to prevent anthracycline-
nduced cardiotoxicity (27).
onclusions
e report here the first evaluation of cardiovascular treat-
ent and consultation practices for cancer patients experi-
ncing decreased LVEF outside the confines of a prospec-
ive clinical trial. The vast majority of patients in our study
ith symptomatic decreased LVEF received cardiology
onsultation and ACEI/ARB therapy, and all received
eta-blocker therapy. However, the majority of cancer
atients in our study with asymptomatic decreased LVEF
id not receive ACEI/ARB or beta-blocker therapy accord-
ng to American College of Cardiology/American Heart
ssociation guidelines. This suggests that closer collabora-
ion between cardiologists and oncologists is needed and
ay have implications for the prevention and treatment of
ardiovascular toxicity among cancer survivors.
eprint requests and correspondence: Dr. Ronald M. Witteles,
ivision of Cardiovascular Medicine, Stanford University School
f Medicine, Falk CVRC 273, 300 Pasteur Drive, Stanford,
alifornia 94305-5406. E-mail: witteles@stanford.edu.
EFERENCES
1. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update
incorporated into the ACC/AHA 2005 guidelines for the diagnosis
and management of heart failure in adults: a report of the American
College of Cardiology Foundation/American Heart Association Task
Force on Practice Guidelines. J Am Coll Cardiol 2009;53:e1–90.
2. Wang TJ, Evans JC, Benjamin EJ, Levy D, LeRoy EC, Vasan RS.
Natural history of asymptomatic left ventricular systolic dysfunction in
the community. Circulation 2003;108:977–82.
3. The SOLVD Investigators. Effect of enalapril on mortality and the
development of heart failure in asymptomatic patients with reduced
left ventricular ejection fractions. N Engl J Med 1992;327:685–91.
4. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic
analysis of adriamycin cardiotoxicity. Cancer 1973;32:302–14.
5. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for
doxorubicin-induced congestive heart failure. Ann Intern Med 1979;
91:710–7.
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
K
1650 Yoon et al. JACC Vol. 56, No. 20, 2010
Left Ventricular Dysfunction After Chemotherapy November 9, 2010:1644–506. National Cancer Institute. Common Terminology Criteria for Ad-
verse Events (CTCAE). Version 4.0. 28 May 2009. Available at:
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/
docs/ctcaev4.pdf. Accessed October 10, 2009.
7. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients
treated with doxorubicin: a retrospective analysis of three trials. Cancer
2003;97:2869–79.
8. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus
a monoclonal antibody against HER2 for metastatic breast cancer that
overexpresses HER2. N Engl J Med 2001;344:783–92.
9. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al., Herceptin
Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant
chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;
353:1659–72.
0. Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac
dysfunction in a randomized trial comparing doxorubicin and cyclo-
phosphamide followed by paclitaxel, with or without trastuzumab as
adjuvant therapy in node-positive, human epidermal growth factor
receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol
2005;23:7811–9.
1. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant
chemotherapy for operable HER2-positive breast cancer. N Engl
J Med 2005;353:1673–84.
2. Slamon DJ, Eiermann W, Robert N, Pienkowski T. Phase III
randomized trial comparing doxorubicin and cyclophosphamide fol-
lowed by docetaxel (ACT) with doxorubicin and cyclophosphamide
with docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin
and trastuzumab (TCH) in HER2-positive early breast cancer pa-
tients: BCIRG 006 study. Breast Cancer Res Treat 2005;94:S5.
3. Slamon DJ, Eiermann W, Robert N, Pienkowski T, Martin M.
BCIRG 006: 2nd interim analysis phase III randomized trial compar-
ing doxorubicin and cyclophosphamide followed by docetaxel (AC-
T) with doxorubicin and cyclophosphamide followed by docetaxel
and trastuzumab (AC-TH) with docetaxel, carboplatin and trastu-
zumab (TCH) in Her2neu positive early breast cancer patients. Paper
presented at: 29th Annual San Antonio Breast Cancer Symposium;
December 15, 2006; San Antonio, TX.
4. Smith I, Procter M, Gelber RD, Guillaume S, Fevereislova A,
Dowsett M. 2-year follow-up of trastuzumab after adjuvant chemo-
therapy in HER2-positive breast cancer: a randomised controlled trial.
Lancet 2007;369:29–36.
5. Herceptin (trastuzumab) package insert. South San Francisco, CA:
Genentech, Incorporated; March 2009. l6. Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-
related cardiotoxicity: Calling into question the concept of reversibility.
J Clin Oncol 2007;25:3525–33.
7. Hospital Compare. U.S. Department of Health & Human Services,
2009. Available at: http://www.hospitalcompare.hhs.gov/Hospital/
Search/SearchMethod.asp. Accessed September 15, 2009.
8. Cockcroft DW, Gault MH. Prediction of creatinine clearance from
serum creatinine. Nephron 1976;16:31–41.
9. Indridason OS, Coffman CJ, Oddone EZ. Is specialty care associated
with improved survival of patients with congestive heart failure? Am
Heart J 2003;145:300–9.
0. Nousiainen T, Jantunen E, Vanninen E, Hartikainen J. Early decline
in left ventricular ejection fraction predicts doxorubicin cardiotoxicity
in lymphoma patients. Br J Cancer 2002;86:1697–700.
1. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthra-
cycline cardiotoxicity: a prospective, blinded, long-term observational
study of outcome in 120 patients. Ann Oncol 2002;13:699–709.
2. Haq MM, Legha SS, Choksi J, et al. Doxorubicin-induced congestive
heart failure in adults. Cancer 1985;56:1361–5.
3. Douglas PS, Khandheria B, Stainback RF, et al. ACCF/ASE/ACEP/
ASNC/SCAI/SCCT/SCMR 2007 appropriateness criteria for trans-
thoracic and transesophageal echocardiography: a report of the Amer-
ican College of Cardiology Foundation Quality Strategic Directions
Committee Appropriateness Criteria Working Group, American So-
ciety of Echocardiography, American College of Emergency Physi-
cians, American Society of Nuclear Cardiology, Society for Cardio-
vascular Angiography and Interventions, Society of Cardiovascular
Computed Tomography, and the Society for Cardiovascular Magnetic
Resonance. J Am Coll Cardiol 2007;50:187–204.
4. Hequet O, Le QH, Moullet I, et al. Subclinical late cardiomyopathy
after doxorubicin therapy for lymphoma in adults. J Clin Oncol
2004;22:1864–71.
5. Hershman DL, McBride RB, Eisenberger A, Tsai WY, Grann VR,
Jacobson JS. Doxorubicin, cardiac risk factors, and cardiac toxicity in
elderly patients with diffuse B-cell non-Hodgkin’s lymphoma. J Clin
Oncol 2008;26:3159–65.
6. Shapiro CL, Hardenbergh PH, Gelman R, et al. Cardiac effects of
adjuvant doxorubicin and radiation therapy in breast cancer patients.
J Clin Oncol 1998;16:3493–501.
7. Riad A, Bien S, Westermann D, et al. Pretreatment with statin
attenuates the cardiotoxicity of Doxorubicin in mice. Cancer Res
2009;69:695–9.
ey Words: anthracyclines y cancer y chemotherapy y heart failure y
eft ventricular dysfunction.
